Thread by @AimHardy

#DDDD

I think the fact that MRx0518 is showing massive near term promise in cancer, yet 4D continue to focus on Parkinson's Disease shows me how excited and effective they believe MRx0029 may be for Parkinson's
(Market expected to reach $8.3bn by 2026)

medgadget.com/2020/02/parkin…

https://twitter.com/AimHardy/status/1348041096874631174

#DDDD $LBPS

After discussing MRx0029 in the text, the author from 4D heavily alludes to bringing in a partner...

#DDDD $LBPS

BOLD Statement

'MRx0029 has shown promise as a potentially
disease-modifying therapy, by indicating a potentially neuro-regenerative effect'

#DDDD

'We are in the process of evaluating designs for a potential first-in-human clinical trial of MRx0029 in patients with PD and have enlisted the help of key opinion leaders in PD clinical study design to assist in planning'

#DDDD

'MRx0002 was able to COMPLETELY PREVENT the onset of disease in an acute experimental autoimmune encephalomyelitis (EAE) animal model of MS, and histological analysis in these models showed significantly reduced inflammation of the spinal cord'

#DDDD

'MRx0002 completely prec(V?)ented the onset of disease, and had very strong efficacy as determined by clinical scoring'